Moderna's Q1 revenues rocket, thanks to ex-US sales
Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
FDA's ODAC delivers one loss, one win for AstraZeneca
The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
Axsome breaks new ground in Alzheimer's with Auvelity OK
Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
Parexel buys Vitrana to boost patient safety toolkit
Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.
GLP-1s drive Lilly's Q1, but it's reticent on oral launch
Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers